Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dengzhan Shengmai
- Development stage
- Phase 4
- Lead developer
- Yunnan Biovalley Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Dengzhan Shengmai is a Traditional Chinese Medicine (TCM) compound formulation primarily used for the treatment and prevention of cardiovascular and cerebrovascular diseases. It is typically composed of four herbal extracts: *Erigeron breviscapus* (Dengzhanxixin), *Panax ginseng*, *Ophiopogon japonicus*, and *Schisandra chinensis*. The formulation is designed to promote blood circulation, resolve blood stasis, and replenish "Qi" and "Yin." It is extensively studied in China for the secondary prevention of ischemic stroke, as well as for treating cognitive impairments such as vascular cognitive impairment and amnestic mild cognitive impairment. Additionally, it is being evaluated for its efficacy in patients with coronary heart disease and heart failure with preserved ejection fraction (HFpEF). The therapeutic effects are attributed to its ability to improve microcirculation, provide neuroprotection, and exert anti-inflammatory and anti-apoptotic effects.
- Brand names
- Dengzhan Shengmai
- Other names
- Dengzhanshengmai capsuleDengzhan Shengmai JiaonangDeng Zhan Sheng Mai
02
Targets
ESR1 (ERα)HDAC1 (Histone Deacetylase 1)PXR (Pregnane X receptor)PGHS-1 (Prostaglandin G/H Synthase 1)CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)IL-6 (Interleukin 6)NMDAR (Glutamate receptor ionotropic, NMDA)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Dengzhan Shengmai.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dengzhan Shengmai.